F. Thionville, 8 INSERM UMR-S1144 and Service de Psychiatrie, Groupe Hospitalier Lariboisiere FW Saint-Louis, p.75010

F. Paris, 9 Service de Biochimie, Groupe Hospitalier Lariboisiere FW Saint-Louis, APHP, 10 Centre Mémoire (CMRR) de Tours, p.37000

F. Strasbourg, 12 Centre Mémoire (CMRR), p.67000

Y. Geda, Baseline Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Population-Based Study, American Journal of Psychiatry, vol.171, issue.5, pp.572-81, 2014.
DOI : 10.1176/appi.ajp.2014.13060821

E. Kokmen, Clinical risk factors for Alzheimer's disease: A population-based case-control study, Neurology, vol.41, issue.9, pp.1393-1400, 1991.
DOI : 10.1212/WNL.41.9.1393

M. Albert, The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011.
DOI : 10.1016/j.jalz.2011.03.008

A. Jorm, History of depression as a risk factor for dementia: an updated review, Australian and New Zealand Journal of Psychiatry, vol.12, issue.6, pp.776-81, 2001.
DOI : 10.1192/bjp.172.6.527

H. Amieva, Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline, Brain, vol.137, issue.4, pp.1167-75, 2014.
DOI : 10.1093/brain/awu035

G. Mckhann, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, issue.7, pp.939-983, 1984.
DOI : 10.1212/WNL.34.7.939

R. Petersen, Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization, Neurology, vol.74, issue.3, pp.201-210, 2010.
DOI : 10.1212/WNL.0b013e3181cb3e25

R. Doody, Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease, New England Journal of Medicine, vol.370, issue.4, pp.311-332, 2014.
DOI : 10.1056/NEJMoa1312889

J. Rinne and K. Nagren, Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease, J Alzheimers Dis, vol.19, issue.1, pp.291-300, 2010.

A. Lim, Clinico-Neuropathological Correlation of Alzheimer's Disease in a Community-Based Case Series, Journal of the American Geriatrics Society, vol.18, issue.4 Suppl, pp.564-573, 1999.
DOI : 10.1111/j.1532-5415.1999.tb02571.x

N. Schoonenboom, Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology, vol.78, issue.1, pp.47-54, 2012.
DOI : 10.1212/WNL.0b013e31823ed0f0

T. Beach, Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005???2010, Journal of Neuropathology & Experimental Neurology, vol.71, issue.4, pp.266-73, 2005.
DOI : 10.1097/NEN.0b013e31824b211b

E. Magnin, Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease, J Alzheimers Dis, vol.39, issue.3, pp.611-617, 2014.

J. Warren, P. Fletcher, and H. Golden, The paradox of syndromic diversity in Alzheimer disease, Nature Reviews Neurology, vol.37, issue.8, pp.451-64, 2012.
DOI : 10.1038/nrneurol.2012.135

G. Mckhann, The diagnosis of dementia due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.263-272, 2011.
DOI : 10.1016/j.jalz.2011.03.005

F. Mouton-liger, Impact of cerebro-spinal fluid biomarkers of Alzheimer???s disease in clinical practice: a multicentric study, Journal of Neurology, vol.8, issue.4, pp.144-51, 2014.
DOI : 10.1007/s00415-013-7160-3

R. Sperling, Toward defining the preclinical stages of Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.280-92, 2011.
DOI : 10.1016/j.jalz.2011.03.003

H. Brunnstrom, Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses, Alzheimer's & Dementia, vol.6, issue.2, pp.104-113, 2010.
DOI : 10.1016/j.jalz.2009.12.005

D. Strozyk, CSF A?? 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, vol.60, issue.4, pp.652-658, 2003.
DOI : 10.1212/01.WNL.0000046581.81650.D0

T. Tapiola, Cerebrospinal Fluid ??-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain, Archives of Neurology, vol.66, issue.3, pp.382-391, 2009.
DOI : 10.1001/archneurol.2008.596

S. Engelborghs, Clinical indications for analysis of Alzheimer's disease CSF biomarkers, Revue Neurologique, vol.169, issue.10, pp.709-723, 2013.
DOI : 10.1016/j.neurol.2013.07.024

P. Gudmundsson, Is there a CSF biomarker profile related to depression in elderly women?, Psychiatry Research, vol.176, issue.2-3, pp.174-182, 2010.
DOI : 10.1016/j.psychres.2008.11.012

A. Troussière, Who needs cerebrospinal biomarkers? A national survey in clinical practice, J Alzheimers Dis, vol.40, issue.4, pp.857-61, 2014.

C. Paquet, Indications, r??alisation et faisabilit?? de la ponction lombaire dans 18??centres m??moires de ressources et de recherche, Revue Neurologique, vol.168, issue.1, pp.28-32, 2012.
DOI : 10.1016/j.neurol.2011.08.012

A. Gabelle, French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study, J Alzheimers Dis, vol.34, issue.1, pp.297-305, 2008.

J. Dumurgier, O. Vercruysse, C. Paquet, S. Bombois, C. Chaulet et al., Intersite variability of CSF Alzheimer???s disease biomarkers in clinical setting, Alzheimer's & Dementia, vol.9, issue.4, pp.406-419, 2013.
DOI : 10.1016/j.jalz.2012.06.006

H. Vanderstichele, L. Shaw, M. Vandijck, A. Jeromin, H. Zetterberg et al., Alzheimer Disease Biomarker Testing in Cerebrospinal Fluid: A Method to Harmonize Assay Platforms in the Absence of an Absolute Reference Standard, Clinical Chemistry, vol.59, issue.4, pp.710-722, 2013.
DOI : 10.1373/clinchem.2012.201830

N. Mattsson, H. Zetterberg, and K. Blennow, Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease, International Journal of Alzheimer's Disease, vol.52, issue.8, p.610613, 2010.
DOI : 10.1007/s00702-006-0511-9

N. Mattsson, The Alzheimer???s Association external quality control program for cerebrospinal fluid biomarkers, Alzheimer's & Dementia, vol.7, issue.4, pp.386-95, 2011.
DOI : 10.1016/j.jalz.2011.05.2243

S. Anthony, The French National Alzheimer Database: A Fast Growing Database for Researchers and Clinicians, Dementia and Geriatric Cognitive Disorders, vol.38, issue.5-6, pp.5-6271, 2014.
DOI : 10.1159/000360281

L. Duff and F. , The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system, J Alzheimers Dis, vol.29, issue.4, pp.891-902, 2012.

J. Dumurgier, Exacerbated CSF abnormalities in younger patients with Alzheimer's disease, Neurobiology of Disease, vol.54, pp.486-91, 2013.
DOI : 10.1016/j.nbd.2013.01.023

K. Blennow, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nature Reviews Neurology, vol.359, issue.3, pp.131-175, 2010.
DOI : 10.1038/nrneurol.2010.4

K. Kobayashi, Pure psychiatric presentation of the Lewy body disease is depression-an analysis of 60 cases verified with myocardial meta-iodobenzylguanidine study, International Journal of Geriatric Psychiatry, vol.66, issue.Suppl 3, pp.663-671, 2015.
DOI : 10.1002/gps.4214

P. Nelson, Low sensitivity in clinical diagnoses of dementia with Lewy bodies, Journal of Neurology, vol.19, issue.3, pp.359-66, 2010.
DOI : 10.1007/s00415-009-5324-y

I. Mckeith, Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium, Neurology, vol.65, issue.12, pp.1863-72, 2005.
DOI : 10.1212/01.wnl.0000187889.17253.b1

S. Gill, Antipsychotic Drug Use and Mortality in Older Adults with Dementia, Annals of Internal Medicine, vol.146, issue.11, pp.775-86, 2007.
DOI : 10.7326/0003-4819-146-11-200706050-00006

B. Kleijer, Risk of cerebrovascular events in elderly users of antipsychotics, Journal of Psychopharmacology, vol.23, issue.8, pp.909-923, 2009.
DOI : 10.1177/0269881108093583

L. Schneider, K. Dagerman, and P. Insel, Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, JAMA, vol.294, issue.15, pp.1934-1977, 2005.
DOI : 10.1001/jama.294.15.1934